Skip to content

menu

Rothwell, Figg, Ernst & Manbeck, P.C. logo
HomeAboutContact
Rothwell Figg's

Biosimilars Law Bulletin

RegulatoryLegalNews

Merial

Subscribe to Merial

PTAB Exercises its § 325(d) Discretion to Deny IPR of Piglet Vaccine Patent

By Benjamin R. Holt on November 5, 2018
Posted in News

The August 2018 Update to the PTAB Trial Practice Guide added guidance regarding the Patent Trial and Appeal Board’s (“the Board”) discretion under 35 U.S.C. § 325(d) to deny institution of an AIA trial when the same or substantially the same prior art or arguments were previously presented to the United States Patent and Trademark…

Blog Editors

Photo of E. Anthony FiggE. Anthony Figg
Photo of Joseph A. HyndsJoseph A. HyndsMember
Photo of Jennifer P. NockJennifer P. NockMember
Photo of Aydin H. HarstonAydin H. HarstonMember

About this Blog

Authored and edited by attorneys in Rothwell Figg’s Biologics and Biosimilars Group, Rothwell Figg’s Biosimilars Law Bulletin provides updates, articles, and analyses regarding regulatory issues, legal decisions, and other news related to biologics and biosimilars under the Biologics Price Competition and Innovation Act (BPCIA).

Read More....

Stay Connected

RSS LinkedIn Twitter Facebook
Subscribe to this blog

Topics

Archives

Blog Authors Show/Hide

  • D. Lawson Allen
  • Nicole M. DeAbrantes
  • Rachel M. Echols
  • Aydin H. Harston
  • Monica Chin Kitts
  • Paul Macri
  • Malissa Magiera
  • An Nguyen
  • Jennifer P. Nock
  • Gary Prato
  • Andrew J. Storaska
  • Vivian Tian
  • Sheena Wang

Recent Posts

  • Janssen and Amgen Settle Stelara BPCIA Case
  • Recent FDA Discussion of Artificial Intelligence for Biosimilar Industry
  • Solicitor General Urges the Supreme Court to Reverse the Federal Circuit’s Teva v. GSK Decision
  • Legislative Efforts to Remove Impediments to Biosimilar Approvals and Marketing
  • How to Effectively Use Patent Counsel to Navigate the USPTO’s Duty of Candor Guidance Regarding FDA Submissions

Rothwell Figg Blogs

  • Healthcare Marketing Law
  • Privacy Zone
  • PTAB Law Blog
  • RF EMerge
  • Trademark Opposition Lawyer
Rothwell, Figg, Ernst & Manbeck, P.C.
Washington, DC
901 New York Avenue, NW
Suite 900 East
Washington, DC 20001
202.783.6040
BiosimilarsIPeditors@rothwellfigg.com
Boston
10 Post Office Square
Suite 800 South
Boston, MA 02109
617.312.3101
BiosimilarsIPeditors@rothwellfigg.com
New York
80 South Highland Ave
Ossining, NY 10562
914.941.5668
BiosimilarsIPeditors@rothwellfigg.com
RSS LinkedIn Twitter Facebook
Privacy PolicyDisclaimer

About Our Firm

To learn more about our firm and other practice areas, visit www.rothwellfigg.com.

Copyright © 2023, Rothwell, Figg, Ernst & Manbeck, P.C.. All Rights Reserved.
Law blog design & platform by LexBlog LexBlog Logo